MORE GREAT NEWS
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
Sight Sciences, Inc.
Tue, November 11, 2025
Sight Sciences, Inc.
Sight Sciences, Inc.
Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical Ophthalmology
MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today the results from three key published manuscripts that further demonstrate the value of an interventional mindset in treating glaucoma.
“We are proud to continuously support the study of interventional glaucoma treatment, especially in highlighting critical groups of patients that may benefit from active surgical interventions. These results demonstrate that when surgeons are given the right solutions, they are able to reduce a patient’s intraocular eye pressure (IOP) and reliance on medication and maintain those reductions over an extended period of time, 24 months or 36 months,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences.
The following are notable results from the studies:
In a 24-month prospective study of 18 eyes with medication washout at baseline, 12 and 24 months, of standalone OMNI use, mean baseline IOP of 26.1 mmHg was reduced an average of 9.7mmHg at 12 months and 10.6 mmHg at 24 months (both p<.001), while mean medications were reduced from 1.8 to 0.9 and 0.5 (both p<.001) at months 12 and 24, respectively; Two-thirds of patients were medication-free at Month 24.1
In a retrospective, observational study of nearly 13,000 African American eyes (including 12,057 cataract surgery only, 491 iStent inject®, 189 Hydrus® Microstent, and 91 OMNI – all minimally invasive glaucoma surgery (MIGS) at the time of cataract surgery), IOP reductions were higher in this study’s MIGS plus cataract surgery cohorts than cataract surgery alone; the proportion of patients with a greater than or equal to 20% reduction in IOP from baseline was greatest for OMNI, followed by Hydrus Microstent and iStent inject 2
In a subgroup analysis of 220 eyes that had undergone a standalone OMNI procedure in primary open-angle glaucoma, including mild, moderate and severe patients, and both phakic and pseudophakic eyes, IOP was significantly reduced for up to 3 years regardless of lens status or disease severity.3
“OMNI continues to deliver results for patients , whether it be patients undergoing cataract surgery, those that have already had cataract surgery and are now pseudophakic, or groups at historically higher risk for glaucoma, as demonstrated by our study,” Dr. Leon Herndon from Durham, NC commented. “It is important to have effective tools such as OMNI that are used especially for mild and moderate patients, and can be utilized in conjunction with a cataract surgery or as a standalone procedure. That is especially true with African American patients, a cohort of patients that are often diagnosed at a later stage of disease.”
AI
